Please login first

Cancers Webinar | Biomarkers for Cancer Immunotherapy

9 Sep 2021, 17:00 (CEST)

Cancer Immunotherapy, Biomarkers, Liquid Biopsy, Melanoma, Checkpoint Therapy, CTC, Circulating Tumor Cells
Bookmark
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chairs

4th Cancers Webinar

Biomarkers for Cancer Immunotherapy

I would like to welcome you to the Cancers Webinar on Biomarkers of Cancer Immunotherapy. As I’m sure you are aware, novel immunotherapy approaches have had a huge impact in improving cancer outcomes and survival, and immunotherapy is now often referred to as the “fourth pillar” of cancer therapeutics along with surgery, radiation, and chemotherapy. While immunotherapy approaches have provided researchers, clinicians, and patients with new hope for defeating this disease, patient responses to immunotherapies vary widely, and much work remains to be done. One of the key questions to address for improved therapeutic outcomes is which patients will respond to which therapies and why? A number of biomarkers have emerged in recent years to help guide clinicians with cancer immunotherapies, and more are being identified and validated every day. In this webinar, we will hear from two leaders in this field, Dr. Eric Tartour (Hôpital Européen Georges-Pompidou) and Dr. Elin Gray (Edith Cowan University), who will give us their insights on how biomarkers can help improve immunotherapeutic treatment regimens for cancer patients.

Date: 9 September 2021

Time: 5:00pm CEST | 11:00am EDT | 11:00pm CST Asia

Webinar ID: 812 5168 6719

Webinar Secretariat: cancers.webinar@mdpi.com

Chair

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

DETAILS
Bio
Carlos S. Moreno, Ph.D. obtained his B.S. and M.S. in Aeronautics and Astronautics from MIT, and worked for NASA before he earned his PhD in Genetics and Molecular Biology from Emory University in 1998. He is Associate Professor of Pathology & Laboratory Medicine and Biomedical Informatics at Emory University, where he is a member of the Winship Cancer Institute. He specializes in cancer bioinformatics and cancer genomics, and his laboratory has used whole genome expression analysis and next-generation sequencing to identify biomarkers of aggressive disease in prostate cancer. He is a co-inventor on a patent application for a system to detect biomarkers using piezoelectric resonators and co-founded ResonanceDx to develop rapid, point-of-care diagnostic devices. He is Director of the PhD Program in Cancer Biology at Emory University and Section Editor-in-Chief of the Cancer Biomarkers section of the journal Cancers.

Invited Speakers

1. Equipe Labellisée Ligue contre le Cancer, Paris, France,
2. Immunology, APHP, Hôpital Europeen Georges Pompidou, Paris, France,
3. Université de Paris, PARCC, INSERM U970, Paris, France

DETAILS
Bio
Eric Tartour, MD, PhD is head of the Immunology department at the Georges Pompidou European Hospital and also director of a research team at INSERM U970 (PARCC)/Université of Paris. His group was a pioneer in demonstrating the interest of targeting antigens to dendritic cells (Haicheur N J Immunol 2000), as well as the need to induce a mucosal immune response to inhibit the growth of tumours located in mucosal sites (Sandoval Sci Transl Med 2013)(Nizard Nat Commun 2017). He has also developed with C Badoual a platform for in situ multiplex immunofluorescence analysis of the tumour microenvironment to identify biomarkers of response to immunotherapy (Granier Cancer Res 2017, Hofman P Cancers 2019). He has published more than 260 articles

School of Medical and Health Sciences, Edith Cowan University, Joondalup WA, Australia

DETAILS
Bio
Associate Professor Elin Gray is a Cancer Council WA Research Fellow, Melanoma Research Group Leader at the School of Medical and Health Sciences, and Deputy Director of the Centre for Precision Health, at Edith Cowan University. Elin completed a BSc in Biochemistry at the University of Havana, Cuba, and obtained her PhD degree at University of Witwatersrand, Johannesburg, South Africa. She was a visiting Fogarty Fellow at the Vaccine Research Centre at the NIH, Maryland; and at Duke University, North Carolina, USA. Since moving to Perth in 2011, her research has focused on identifying diagnostic and prognostic blood-based biomarkers for melanoma. She utilises novel techniques and genetic analysis methodologies to study of blood biomarkers such as circulating tumour cells, circulating tumour DNA and exosomes. Her aim is to develop of liquid biopsies that can provide important tumour-specific information that can guide the selection of the best treatment strategy for cancer patients.

Program

Speaker/Presentation

Time in CEST/CET

Prof. Dr. Carlos S. Moreno

Chair Introduction

5:00 pm – 5:10 pm

Prof. Dr. Carlos S. Moreno

Current Challenges in Immunotherapy

5:10 pm – 5:30 pm

Prof. Dr. Eric Tartour

Biomarker tracking the interaction between immune system and tumor predicts response to immunotherapy

5:30 pm – 5:50 pm

Prof. Dr. Elin S. Gray

Potential for Liquid Biopsy Modalities to Track and Guide Immunotherapy Treatment of Melanoma

5:50 pm – 6:10 pm

Q&A Session

6:10 pm – 6:30 pm

Closing of Webinar

Chair Prof. Dr. Carlos S. Moreno

6:30 pm – 6:35 pm

Webinar Content

On Thursday 9 September 2021, MDPI and the Journal Cancers organized their 4th webinar, entitled "Biomarkers for Cancer Immunotherapy".

The introduction and first talk were held by the Chair of the webinar, Prof. Dr. Carlos S. Moreno from Emory University School of Medicine, USA. Prof. Dr. Moreno kicked off the webinar with his presentation entitled “Current Challenges in Immunotherapy”. Prof. Dr. Moreno is Associate Professor of Pathology & Laboratory Medicine and Biomedical Informatics at Emory University, where he is a member of the Winship Cancer Institute. He specializes in cancer bioinformatics and cancer genomics, and his laboratory has used whole genome expression analysis and next-generation sequencing to identify biomarkers of aggressive disease in prostate cancer.

The second presentation with the title "Biomarker Tracking the Interaction between Immune System and Tumor Predicts Response to Immunotherapy" was held by Prof. Dr. Eric Tartour from Université de Paris, France. Eric Tartour, MD, PhD is head of the Immunology department at the Georges Pompidou European Hospital and also director of a research team at INSERM U970 (PARCC)/Université of Paris. His group was a pioneer in demonstrating the interest of targeting antigens to dendritic cells (Haicheur N J Immunol 2000), as well as the need to induce a mucosal immune response to inhibit the growth of tumours located in mucosal sites (Sandoval Sci Transl Med 2013)(Nizard Nat Commun 2017).

Prof. Dr. Elin S. Gray from Edith Cowan University, Australia was the third and final speaker and her presentation was entitled “Potential for Liquid Biopsy Modalities to Track and Guide Immunotherapy Treatment of Melanoma”. Associate Professor Elin Gray is a Cancer Council WA Research Fellow, Melanoma Research Group Leader at the School of Medical and Health Sciences, and Deputy Director of the Centre for Precision Health, at Edith Cowan University. Her aim is to develop of liquid biopsies that can provide important tumour-specific information that can guide the selection of the best treatment strategy for cancer patients.

The presentations were followed by a Q&A and a discussion, moderated by the Chair. The webinar was offered via Zoom and required registration to attend. The full recording can be found here on Sciforum website. In order to stay updated on the next webinars on Cancers, be sure to sign up for our newsletter by clicking on “Subscribe” at the top of the page.

Relevant SI

Circulating Biomarker in Malignant Melanoma
Guest Editor: Prof. Dr. Elin S. Gray
Deadline for manuscript submissions: 28 February 2022

Cancer Glycobiomarkers Facing Precision Oncology
Guest Editor: Prof. Paula A. Videira & Dr. José Alexandre Ferreira
Deadline for manuscript submissions: 30 April 2022

Biomarkers in the Era of Precision Oncology
Guest Editor: Prof. Dr. Constantin N. Baxevanis
Deadline for manuscript submissions: 1 March 2022

Topical Collection:

Cancer Biomarkers
Collection Editor: Dr. Carlos S. Moreno

Sponsors and Partners

Organizers

Top